RecruitingACTRN12611000146998

Predicting the Response of Treatment in Cardiomyopathy

Predictors of Response to Therapy in New-Presentation Idiopathic Dilated Cardiomyopathy

Sponsor

Professor Joseph Selvanayagam

Enrollment

200 participants

Start Date

Jul 5, 2008

Study Type

Observational

Conditions

Idiopathic Dilated Cardiomyopathy

Summary

Heart Failure (HF) is a leading cause of heart disease and mortality in developed countries. It is the leading reason for hospital admission among patients over 65 years and the most costly cardiovascular disorder in Western countries. A first hospital admission for HF has been shown to confer a worse prognosis than a first admission for bowel or breast cancer. The burden of HF is expected to increase in Australia due to the ageing population and improved survival from acute cardiac events. New cardiac imaging tools, such as cardiac MRI and novel applications of echocardiography (ultrasound of the heart), now permit an insight into some of the fundamental processes that underlie why some individuals don’t respond to conventional HF treatment. In particular, our research will focus on the scarring within the heart muscle, and the loss of coordination of the heart as it pumps, in perpetuating the vicious HF cycle. Furthermore, we will explore the role of a simple blood test, to measure markers of scarring from the heart, in predicting patient outcomes in the setting of a new diagnosis of HF. An understanding of these elements in the pathogenesis of cardiomyopathy will help clarify the mechanistic cascade of HF, and may thus lead to novel therapies to interrupt such an adverse process. This research may thus change the way cardiomyopathy is viewed and treated.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

Heart failure (HF) is a serious condition where the heart is not pumping blood as effectively as it should, causing symptoms like breathlessness, fatigue, and fluid buildup. This study is using advanced heart imaging — cardiac MRI and specialized ultrasound — to look at scarring in the heart muscle and how the heart moves when it pumps. Researchers are also testing whether a simple blood test can predict how well patients will respond to heart failure treatment, which could lead to better, more personalized care. You may be eligible if: - You are 18 years or older - You have been newly diagnosed with heart failure (New York Heart Association class II–IV) - Your heart's pumping function (left ventricular ejection fraction) is less than 45% on an imaging test You may NOT be eligible if: - You have a pacemaker or implantable defibrillator (these prevent MRI scanning) - You have severe claustrophobia (you cannot tolerate an MRI machine) - You have significant blockages in your heart arteries (coronary artery disease with more than 70% narrowing or a significant area of damaged heart muscle) - Your heart failure is mainly caused by a leaky or narrowed heart valve (other than a secondary leaky mitral valve) - You have specific conditions such as hypertrophic cardiomyopathy, myocarditis, amyloidosis, or sarcoidosis - Your kidneys are not working well enough to safely receive an MRI dye (gadolinium) - You are too breathless to exercise (NYHA class IV) Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

6-minute walk test, Minnesota Living with Heart Failure Questionnaire, NYHA classification, Cardiopulmonary exercise testing, Echocardiogram and CMR will all be performed at baseline, 6 months and 12

6-minute walk test, Minnesota Living with Heart Failure Questionnaire, NYHA classification, Cardiopulmonary exercise testing, Echocardiogram and CMR will all be performed at baseline, 6 months and 12 months. To complete all these investigations would take approximately 2 hours, at each time point. We will examine the relationship between these parameters and response to conventional heart failure therapy.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000146998

Related Trials

Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling

NCT063567279 locations